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Abstract 
Recently, interest in IL-15-differentiated cells has increased; however, the phenotypic definition of 
IL-15-differentiated bone marrow-derived cells (IL-15-DBMCs) is still under debate, particularly the 
generation of IFN-γ-producing innate cells such as premature NK (pre-mNK) cells, natural killer 
dendritic cells (NKDCs), interferon-producing killer dendritic cells (IKDCs), and type 1 innate lymphoid 
cells (ILC1s), all of which are IL-15-dependent. Here, we revisited the immunophenotypic characteristics 
of IFN-γ-producing IL-15-DBMCs and their functional role in the control of intracellular Mycobacterium 
tuberculosis (Mtb) infection. When comparing the cytokine levels between bone marrow-derived 
dendritic cells (BMDCs) and IL-15-DBMCs upon stimulation with various TLR agonists, only the CD11cint 
population of IL-15-DBMCs produced significant levels of IFN-γ, decreased levels of MHC-II, and 
increased levels of B220. Neither BMDCs nor IL-15-DBMCs were found to express DX5 or NK1.1, 
which are representative markers for the NK cell lineage and IKDCs. When the CD11cintB220+ 
population of IL-15-DBMCs was enriched, the Thy1.2+Sca-1+ population showed a marked increase in 
IFN-γ production. In addition, while depletion of the B220+ and Thy1.2+ populations of IL-15-DBMCs, but 
not the CD19+ population, inhibited IFN-γ production, enrichment of these cell populations increased 
IFN-γ. Ultimately, co-culture of sorted IFN-γ-producing B220+Thy1.2+ IL-15-DBMCs with Mtb-infected 
macrophages resulted in control of the intracellular growth of Mtb via the IFN-γ-nitric oxide axis in a 
donor cell number-dependent manner. Taken together, the results indicate that IFN-γ-producing 
IL-15-DBMCs could be redefined as CD11cintB220+Thy1.2+Sca-1+ cells, which phenotypically resemble 
both IKDCs and ILC1s, and may have therapeutic potential for controlling infectious intracellular bacteria 
such as Mtb. 
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Introduction 
Interleukin (IL)-15 is a multipotent cytokine with 
immunoregulatory properties that is produced by 
various cell types, but it is predominantly expressed 
by myeloid cells (1). In general, IL-15 serves as a 
growth factor by promoting the survival and 
differentiation of lymphoid cells such as T, B, and NK 
cells. Thus, IL-15 is thought to play an essential role in 
the development, homeostasis and maintenance of 
those cell types. In addition, IL-15 also serves multiple 
functions including regulating the T cell response and 
B cell homing, modulating inflammation, activating 
NK cells, and connecting the innate and adaptive 
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immune systems via regulating the function of 
dendritic cells (DC) and macrophages. Thus, IL-15 has 
therapeutic potential in many diseases, including 
cancer and infectious diseases, because this cytokine 
is thought to be an instructive cytokine involved in 
cell fate decisions that favor immunoregulatory 
function (1-3).  
Since IL-15 was discovered, its biological 
applications and IL-15-based immunotherapy have 
been further highlighted by clinical trials focused on 
improving the immune response and the 
development of vaccines against infections and 
cancers (3). In fact, according to the National Cancer 
Institute (NIH, USA), of the 12 immunotherapeutic 
agents that have been used for treating cancer or for 
the development of cancer vaccines, IL-15 ranks first 
on the list because of its better ability to induce 
longer-lived T cells with higher avidity and its 
increased safety for tumor therapy compared to other 
cytokines such as IL-2 and IL-12 (4). Along with the 
anticipated uses for IL-15 in cancer treatment, IL-15 
therapy shows promise for treating various infectious 
diseases. For example, IL-15 therapy boosts the 
anti-HIV immunity by regulating IFN-γ secretion 
with the enhanced survival of CD8+ T cells 
independent of CD4+ T cells (5,6). In addition, the use 
of IL-15 as an adjuvant in vaccine formulation 
enhanced the protective immunity against many 
intracellular pathogens, including influenza virus, 
Toxoplasma gondii, and herpes simplex virus, by 
increasing the survival and cytotoxicity of T and NK 
cells as well as by increasing IFN-γ production (5,7). 
Taken together, these previous studies suggest that 
IL-15 is associated with the development of 
IFN-γ-mediated Th1-biased response and exhibits 
potential for maintaining long-lasting T cell responses 
to pathogens (8). 
Although the direct use or genetic modification 
of IL-15 has been implemented as a therapeutic 
against various diseases, its role in immune 
reconstitution by regulating immune cell 
differentiation is of particular interest. For example, 
IL-15 can facilitate immune reconstitution after bone 
marrow transplantation (9). In addition, human 
recombinant IL-15 facilitates the reconstitution of 
human T cells in the thymus and spleen in NOD-SCID 
mice (10). 
IL-15 is considered an important candidate for 
the reconstitution of DC-mediated immune 
responses (11). Dendritic cells (DCs) are potent 
antigen-presenting cells (12) that are essential for 
linking the innate and adaptive immune responses. 
Based on the potent immune-activating properties of 
DCs, their use in the production of cellular vaccines is 
an appealing strategy for cancer immunotherapy and 
treatment of infectious diseases (13-15). Instead of the 
commonly used methods for DC differentiation, 
which use IL-4 for rapid expansion of DCs and 
introduce a possible risk of contamination during in 
vitro culture (16-20), an alternative method for DC 
differentiation involving the combination of 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and IL-15 has also been widely used (13). 
Previous studies have reported that 
IL-15-differentiated DCs exhibit a distinct Langerhans 
cell-like phenotype and possess unique 
immunostimulatory properties (21,22). Thus far, 
studies examining the abilities of IL-15-differentiated 
DCs have mostly focused on their better efficacy for T 
cell stimulation (11,23,24). Interestingly, previous 
studies reported that IL-15-differentiated DCs are 
capable of expressing IFN-γ (13,25); however, 
myeloid cell lineages expressing IFN-γ have been 
disputed in many studies (26-28).  
Chan et al. first discovered a third type of DCs, 
termed the interferon-producing killer dendritic cells 
(IKDCs), and thus proved that DCs could induce 
IFN-γ production (29-31). As IKDCs were absent in 
IL-2/IL-15 receptor beta chain-deficient mice (29), 
IL-15 was considered a key factor for the development 
of IKDCs. Moreover, trans-presentation, a unique 
IL-15 signaling mechanism, was demonstrated to be 
involved in the expansion of IKDCs in vitro and in 
vivo (32). IKDCs were previously reported to express 
CD11clowB220+, even though the specific markers 
were different from each other (32-35). These markers 
are known as NK cell surface markers, which have led 
to controversy over the lineage of this type of 
cells (34,36). According to their unique pathway for 
differentiation from bone marrow (37), ability to 
respond to IL-15 (32), and distinct transcriptional 
profile from that of NK cells (38), IKDCs seemingly 
belong to a subpopulation of DCs that differs from 
NK cells (34). More recently, these IKDCs exhibiting 
features of both NK cells and DCs (29,31,36) now have 
been revisited as part of the NK cell lineage and have 
been renamed as premature NK cells (pre-mNK cells), 
resulting in an endless lineage debate (36,39,40). 
As another innate cell source of IFN-γ, this 
emerging cell family is formally now defined as 
innate lymphoid cells (ILCs) and has been recently 
identified as a part of the innate immune system, 
playing crucial roles in immunity, inflammation and 
tissue remodeling (41). This cell family has been 
categorized into three main groups, ILC1, ILC2 and 
ILC3, according to their cytokine-producing ability 
and transcription factor expression (42). Among the 
three cell groups, ILC1s were originally believed to be 
a homogeneous population consisting of solely NK 
cells. Interestingly, this putative homogeneous 
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population has now been further classified into two 
heterogeneous subsets, NK cells and T-bet-dependent 
IFN-γ secreting innate cells that reside within 
peripheral tissues (43-46). These heterogeneous ILC1s 
especially share the ability to produce IFN-γ in 
response to IL-12, IL-15 and IL-18 cytokines, thus 
contributing to enhanced immunity against infectious 
disease (41,47,48). Moreover, IL-15 is required for 
ILC1 development and maintenance (47,49,50). 
Therefore, IL-15 may play an important role in 
contributing to the generation of ILC1 subsets. 
However, distinguishing the two subsets is 
challenging because of their phenotypical changes 
during inflammation (42,51,52). 
In view of the debates over the use of IL-15 for 
immune cell differentiation and the use of IL-15 in the 
phenotypic characterization of incompletely defined 
IFN-γ-producing innate cells such as IKDCs or 
pre-mNK cells, NK cells, NKDCs and ILC1s, in the 
present study, we revisited the phenotypic 
characteristics of the IFN-γ-producing 
IL-15-differentiated bone marrow-derived cells, 
hereafter referred to as IL-15-DBMCs (addition of 
IL-15 during DC differentiation with GM-CSF 
with/without IL-4 conventionally from bone 
marrow). We therefore compared the levels of 
cytokines and surface markers, including well-known 
cell markers for IKDCs or pre-mNK cells, NK cells, T 
cells, B cells and ILC1s in IL-15-DBMCs. In addition, 
we attempted to redefine specific markers on 
IFN-γ-producing cell population in IL-15-DBMCs by 
enrichment or depletion of specific markers on the 
IL-15-DBMCs using FACS or magnetic activated cell 
sorting (MACS) systems. Additionally, it has been 
reported that common gamma-chain cytokines, 
including IL-15, improve anti-bacterial and anti-viral 
immunity via the enhanced T cell response followed 
by potentiating the intracellular pathogen-killing 
function of macrophages, which supports its use in 
the treatment of severe infectious diseases caused by 
Mycobacterium tuberculosis (Mtb), human 
immunodeficiency virus and hepatitis B virus (53). 
Therefore, we assessed whether exploiting these 
IFN-γ-producing IL-15-DBMCs can be extended to the 
therapeutic potential for infectious diseases such as 
TB by examining the immune responses to 
Mtb-infected macrophages. 
Materials and Methods 
Ethics statement 
All animal experiments were performed 
according to the guidelines of Korean Food and Drug 
Administration. Protocols for animal studies used in 
the study were approved by the Ethics Committee 
and Institutional Animal Care and Use Committee 
(2017-0049; C57BL/6J) of Yonsei University Health 
System (Seoul, Korea).  
Animals 
After approval of the study experiments, 6- to 
7-week-old C57BL/6 female mice were purchased 
from Japan SLC, Inc. (Shizuoka, Japan) and 
maintained under specific pathogen-free (SPF) 
conditions. IFN-γR-/- mice in a C57BL/6J background 
were purchased from the Jackson Laboratory (Bar 
Harbor, ME, USA). 
Reagents 
Murine recombinant IL-15 (R&D, Minneapolis, 
MN, USA) and TLR agonists, lipopolysaccharide 
(LPS; E. coli 0111:B4), synthetic triacylated lipoprotein 
(Pam3CSK4), synthetic analog of dsRNA (Poly(I:C) 
HMW), and class B CpG oligonucleotide (ODN 1826) 
were purchased from Invivogen Inc. (San Diego, CA, 
USA). 
Generation and culture of BMDCs and 
IL-15-DBMCs 
BMDCs were generated from murine bone 
marrow cells with GM-CSF alone or GM-CSF plus 
IL-4 as previously described (54). Briefly, bone 
marrow cells were plated in petri dishes with RPMI 
1640 medium supplemented with 100 units/ml 
penicillin/streptomycin (Lonza, Basel, Switzerland), 
10% fetal bovine serum (Lonza, Basel, Switzerland), 
50 µM mercaptoethanol (Lonza), and 20 ng/ml of 
GM-CSF alone or GM-CSF plus 5 ng/ml of IL-4 and 
were cultured at 37°C in the presence of 5% CO2. 
IL-15-DBMCs were prepared and cultured under the 
same differentiation conditions but in the BMDC 
medium supplemented with 10 ng/ml of IL-15. On 
day six, the subsequent experiments, including an 
analysis of cytokine levels and surface marker 
expression, were conducted.  
Cytokine measurements 
On day six of culture, cells were harvested for 
analysis and plated onto 12-well multi-well plates in 
the presence or absence of TLR agonists: 100 ng/ml of 
Pam3CSK4, 1 µg/ml of Poly(I:C), 100 ng/ml of LPS or 
1 µg/ml of ODN. Cells were incubated for 24 h, and 
then cell supernatants were collected. Supernatants 
were stored at -80°C until use. The levels of IL-6, 
TNF-α, IL-12p70, IL-10, and IFN-γ were determined 
by commercially available ELISA kits according to the 
manufacturer’s instructions (eBioscience, San Diego, 
CA and BD Bioscience, San Diego, CA). 
Flow cytometry 
To detect the expression of surface molecules on 
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both cell types, cells were washed with DPBS 
(Welgene Inc., Daegu, Korea) and blocked with a 
highly specific anti-mouse CD16/CD32 (2.4G2, IgG2b, 
κ) antibody. The cell surface was stained with 
fluorescein isothiocyanate (FITC)-conjugated, 
anti-CD19 (eBio1D3, Rat IgG2a, κ), anti-CD11b 
(M1/70, Rat IgG2b, κ); Alexa 488-conjugated 
anti-CD8a (53-6.7, Rat IgG2a, κ) and anti-B220 
(RA3-6B2, Rat IgG2a, κ); Phycoerythrin 
(PE)-conjugated anti-Thy1.2 (30-H12, Rat IgG2b, κ), 
anti-CD49b (DX5, Rat IgM, κ), anti-CD19 (eBio1D3, 
Rat IgG2a, κ), and anti-MHC-II (M5/114.15.2, Rat 
IgG2b, κ); Peridinin Chlorophyll (PerCP)-eFluor® 
710-conjugated anti-PDCA-1 (eBio927, Rat IgG2b, κ), 
anti-Siglec-H (eBio440c, Rat IgG2b); 
PerCP-Cy5.5-conjugated anti-CD4 (RM4-5, Rat IgG2a, 
κ), and anti-CD11b (M1/70, Rat IgG2b, κ); 
PE-Cy7-conjugated anti-CD11c (HL3, Hamster IgG1, 
λ1); Allophycocyanin (APC)-conjugated anti-B220 
(RA3-6B2, Rat IgG2a κ), anti-Thy1.2 (53-2.1, Rat 
IgG2a κ) and anti-CD49b (DX5, Rat IgM, κ); Alexa 
647-conjugated anti-CD3 (17A2, Rat IgG2b, κ); 
APC-eFluor® 780-conjugated anti-MHC-II 
(M5/114.15.2, Rat IgG2b, κ), anti-CD127 (A7R34, Rat 
IgG2a, κ) and anti-NK1.1 (PK136, Mouse IgG2a, κ); 
and V605-conjugated anti-Sca-1 (D7, Rat IgG2a, κ). 
Before use, the antibodies were diluted with DPBS 
containing 2% FBS. Cells were stained for 20 to 30 min 
in the dark on the ice. Before analysis, samples were 
washed with DPBS containing 2% FBS. For 
intracellular cytokine staining, BD Cytofix/Cytoperm 
kit (BD Pharmingen, San Diego, CA, USA) was used 
following the manufacturer’s instructions. The levels 
of intracellular cytokines were detected with 
PE-conjugated anti-IFN-γ (XMG1.2, Rat IgG1, κ). All 
antibodies were purchased commercially 
(eBioscience, San Diego, CA, USA and BD 
Pharmingen, San Diego, CA, USA). Prepared samples 
were acquired on the FACSVerse or FACSCanto II 
flow cytometer (BD Biosciences, San Jose, CA, USA) 
and analyzed using FlowJo software (Tree Star, 
Ashland, OR, USA). 
Morphological analysis 
Cells cultured with GM-CSF or GM-CSF plus 
IL-15 were harvested and washed. Cells were 
cytospun in a Shandon Cytospin 3 (Thermo Scientific, 
Marietta, Ohio, USA) at 1000 rpm for 5 min on slides 
with double cytofunnel sample chambers (Shandon, 
Thermo Scientific). Subsequently, slides were allowed 
to air dry and were immediately fixed with methanol 
(SIGMA, Aldrich, Saint Louis, MO, USA). Cells were 
stained in May-Grünwald-Giemsa stain diluted in 9 
volumes of distilled water for 5 min and washed with 
tap water. Slides were examined by light microscopy. 
FACS cell sorting  
On day six of culture, both groups of cells were 
grown in medium with GM-CSF alone, and cells 
grown in medium with GM-CSF and IL-15 were 
harvested and stained with PE-Cy7-conjugated 
anti-CD11c antibody. After staining, the cells were 
washed with sorting buffer containing DPBS, 2 mM 
EDTA (USB, Cleveland, OH, USA), 25 mM HEPES 
solution (4-(2-hydroxyethyl)piperazine-1-ethanesulfo-
nic acid solution) (Sigma, St. Louis, MO, USA), and 
2% bovine serum albumin (Sigma). Cell sorting was 
performed with a FACSAria (BD Biosciences, San 
Jose, CA, USA). The purity of the cell separation was 
over 94%. 
MACS 
To enrich or deplete cells expressing the targeted 
markers, antibody-conjugated magnetic beads were 
used for cell sorting. On day six of culture, both 
groups of cells were harvested, and CD 90.2, B220, 
and CD19 MicroBeads (Miltenyi Biotce, Bergisch 
Gladbach, Germany) were used according to the 
manufacturer’s instructions with the QuadroMACS 
separation unit attached to a MACS multi-stand and 
LS or LD columns. 
Bacterial strains and cultures 
M. tuberculosis strain H37Rv, stored at the 
International Tuberculosis Research Center (ITRC, 
Masan, Korea), was used in this study. M. tuberculosis 
was cultured aerobically at 37°C in Middlebrook 7H9 
medium (Difco Laboratories, Detroit, MI, USA) 
containing 0.02% glycerol (Sigma, Saint Louis, MO, 
USA) supplemented with 10% oleic 
acid-albumin-dextrose-catalase (OADC) (Becton 
Dickinson, Sparks, MD, USA) for 4 weeks. 
Enumerated bacteria were used for the subsequent 
macrophage infection experiment as described below.  
Nitric oxide detection 
Nitric oxide (NO) was detected with enzymatic 
reduction of NO3 by nitrate reductase, followed by 
spectrophotometric analysis of total nitrite using 
Griess reagent. This method was conducted according 
to the manufacturer’s instructions (iNtRON 
Biotechnology, Gyeonggi, Korea). 
Growth of M. tuberculosis in bone 
marrow-derived macrophages (BMDMs) 
co-cultured with sorted IFN-γ-producing 
IL-15-DBMCs  
To compare the effect of pathogenesis of the M. 
tuberculosis strain H37Rv on infected macrophages 
with added cells, BMDMs were infected at one 
bacterium per cell in antibiotic-free DMEM (Biowest, 
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Nuarille, France) and incubated for 4 h. The wells 
were then thoroughly washed with prewarmed DPBS 
to remove extracellular bacteria and then incubated 
again in antibiotic-free media for the adaptation of the 
bacteria in cells. After 24 h of incubation, each well 
was washed with DPBS, and Mtb-infected BMDMs 
were co-cultured with the sorted cells from 
IL-15-DBMCs; cells were added to the MOI of 1:1 
or/and 1:5. Three days after infection, cells were lysed 
with 0.05% Triton X-100 (Sigma) prepared in sterile 
water. The lysates were serially diluted in sterile 
DPBS and spotted onto Middlebrook 7H10 agar 
(Difco) supplemented with 10% OADC. The bacterial 
colony-forming units (CFU) were enumerated after 
the bacteria were incubated for 4 weeks at 37°C. 
Statistical analysis  
All the experiments were repeated at least three 
times with consistent results. Representative data in 
the graphs are presented as the mean ± standard 
deviation (SD). The data comparisons from the 
experiment among samples were determined by an 
unpaired t-test or one-way ANOVA followed by 
Tukey’s multiple comparison test distribution using 
statistical software (GraphPad Prism Software, 
version 5.0, San Diego, CA, USA). Statistical 
significance was considered at *p < 0.05, **p < 0.01, 
and ***p < 0.001. 
Results 
Addition of IL-15 to DC differentiation 
conditions generates IFN-γ-producing cells 
with differential expression levels of DC 
surface markers 
The generation of IFN-γ-producing innate cells, 
such as IKDCs or pre-mNK cells, NKDCs, and ILC1s, 
is known to be IL-15-dependent (29,36,47). To confirm 
how IL-15 affects cell differentiation and the 
generation of IFN-γ-producing cells, we used an 
ELISA to measure the levels of various cytokines, 
such as IL-12p70, TNF-α and IFN-γ, followed by LPS 
stimulation. The total number of generated cells was 
not different between BMDCs (1.8 x 108 cells/mouse) 
and IL-15-DBMCs (1.7 x 108 cells/mouse) after 6 days 
of culture. While there was no significant difference 
in the production of TNF-α between the BMDCs and 
IL-15-DBMCs, the level of IFN-γ was dramatically 
up-regulated in the IL-15-DBMCs only after the LPS 
treatment (Fig. 1A). Moreover, compared to BMDCs, 
IL-15-DBMCs began producing IFN-γ at 3 hours 
post-stimulation (Fig. S1A). Regarding IL-12p70, 
although IL-15-DBMCs appeared to produce more 
IL-12p70 than BMDCs, both cells produced IL-12p70 
to some extent; moreover, BMDCs had no ability to 
produce IFN-γ. Additionally, while both BMDCs and 
IL-15-DBMCs displayed similar TNF-α-producing 
capacities against differential TLR agonist 
stimulation, except for under Poly(I:C) stimulation, 
IFN-γ production was observed in IL-15-DBMCs 
only, not in BMDCs (Fig. S1B). Thus, we 
hypothesized that an IL-15-specific cell population, 
which was generated by IL-15 addition during DC 
differentiation, produces IFN-γ and that the entire 
IL-15-DBMC population can produce IFN-γ in 
response to various TLR agonists. IL-4, which has 
been used for in vitro DCs by some groups, is known 
to inhibit DC-produced IL-12p70 and to be involved 
in the development of Th2 cells (24). Therefore, we 
confirmed whether IL-4 affects the cytokine profile 
patterns. While the levels of IFN-γ, IL-12p70, IL-10 
and TNF-α were higher in cells cultured in 
GM-CSF-only medium than in cells cultured in 
GM-CSF plus IL-4 medium, the cytokine profile 
patterns of BMDCs and IL-15-DBMCs were not 
affected by IL-4 (Fig. S2A). Moreover, the 
concentration of GM-CSF rarely impacted cytokine 
production levels (Fig. S2B). Regarding 
morphological features, no differences in size or 
granularity were observed between the two cell 
types based on forward scatter and side scatter plots 
(Fig. 1B). Moreover, a population of non-adherent 
floating cells was observed among the IL-15-DBMCs 
that was morphologically similar to BMDCs on day 
six of culture (Fig. S2C), and this population was 
obvious despite more abundant dark granules in the 
IL-15-DBMCs. Interestingly, IL-15 addition reduced 
the percentage of CD11c+MHC-II+ cells, which are 
mature DC markers (Fig. 1C). Moreover, while the 
CD11chi population in IL-15-DBMCs was lower than 
that of BMDCs, the CD11cint population significantly 
increased, and the MHC-IIlo population expanded 
(Fig. 1D). These results suggest that IL-15 addition 
during DC differentiation generates a phenotypically 
distinguishable IL-15-DBMC population with 
IFN-γ-producing capacity. 
Primary phenotypic characterization of 
IFN-γ-producing CD11cint populations in 
IL-15-DBMCs 
IFN-γ production and the CD11cint population 
appear to be distinct events in IL-15-DBMCs. Thus, 
we presumed that there would be a correlation 
between the expression of CD11c and the production 
of IFN-γ. We performed cell sorting with a FACSAria 
to separate the three cell populations depending on 
the mean fluorescence of CD11c (Fig. 2A). 
Interestingly, after LPS stimulation for 24 h, the levels 
of TNF-α in the BMDCs and IL-15-DBMCs were 
similar in all three populations. In contrast, a 
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significant increase in the level of IFN-γ production 
was observed in the CD11cint population only in 
IL-15-DBMCs, and both CD11chi and CD11c- 
IL-15-DBMCs produced negligible amounts of IFN-γ 
(Fig. 2B). IKDCs (IFN-γ producing killer dendritic 
cells) and plasmacytoid dendritic cells (pDCs) are 
known for their intermediate CD11c expression (55). 
Therefore, we evaluated the levels of various markers 
specific for IKDCs or pDCs for further 
characterization. Moreover, we analyzed markers that 
were specifically expressed in the CD11cint cell 
population in IL-15-DBMCs but not in BMDCs (Fig. 
2C). BMDCs and the CD11cint cell population in 
IL-15-DBMCs did not exhibit differences in the mean 
fluorescence of CD4, CD8, PDCA-1, NK1.1, CD49b or 
Siglec-H. However, the CD11cint cell population in 
IL-15-DBMCs expressed considerably lower levels of 
CD11b and MHC-II and higher levels of B220 than 
those expressed in BMDCs. Consequently, the level of 
B220 expression in the CD11cint cell population in 
IL-15-DBMCs was also significantly higher than that 
in either the BMDC-derived CD11cint population or 
the IL-15-derived CD11chi population (Fig. S3). For the 
subsequent experiments, we excluded conditions 
where there were no alterations or conditions where 
ambiguous markers were expressed on the CD11cint 
cell population in IL-15-DBMCs compared with those 
on BMDCs.  
 
 
Figure 1. IL-15-differentiated bone marrow-derived cells (IL-15-DBMCs) produced significant levels of IFN-γ along with decreased levels of common 
dendritic cell markers. (A-D) BMDCs or IL-15-DBMCs were differentiated from bone marrow in the presence of GM-CSF alone or GM-CSF plus IL-15, respectively. (A) 
Scheme of the experimental design for cell generation. Bone marrow cells treated with or without (red arrow) IL-15 on day 0 of cell generation were subsequently treated with 
media at 3 days post cell culture (blue arrow). After 6 days of culture, each differentiated cell population (106/ml) was stimulated with 100 ng/ml of LPS for 24 h (dashed arrow). 
Cytokines were measured by ELISA with culture media (mean ± SD; n = 3). (B) Each cell population group was analyzed by forward scatter and side scatter via flow cytometric 
analysis. One representative plot from three independent experiments is described. (C) Expression of CD11c and MHC-II in each group of cells. The number of squares indicates 
the percentage of the corresponding population. The proportion of CD11c+MHC-II+ cells is represented by bar charts (mean ± SD; n = 3). (D) Expression of CD11c and MHC-II 
in each group of cells. The proportions of CD11chiMHC-IIhi, CD11chiMHC-IIlo, CD11cintMHC-IIhi, and CD11cintMHC-IIlo cells are represented by dot plot, bar, and pie charts 
(mean ± SD; n = 3). The significance of differences was determined using an unpaired t-test. n.s.; not significant, ***p < 0.001 comparison between BMDCs and IL-15-DBMCs. 
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Figure 2. CD11cint population in IL-15-DBMCs is a major source of IFN-γ production and differentially expresses surface markers in comparison with 
BMDCs. (A) CD11c+, CD11cint, and CD11c- population in BMDCs and IL-15-DBMCs were isolated by FACS. One representative plot from three independent experiments 
is described. (B) Each sorted cell population (105/ml) was stimulated with 100 ng/ml of LPS for 24 h. Cytokines were measured by ELISA with culture media (mean ± SD; n = 
3). (C) On day of six, BMDC-derived CD11chi and IL-15-DBMC-derived CD11cint cells were stained for the indicated markers and compared between the two cell populations. 
The number of squares indicates the percentage of the corresponding population. One representative plot from three independent experiments is described. The significance of 
the difference was determined using an unpaired t-test. n.s.; not significant, *p < 0.05, **p < 0.01, ***p < 0.001 comparison between BMDC and IL-15-DBMCs. 
 
Advanced phenotypic characterization of 
IFN-γ-producing CD11cintB220+ populations in 
IL-15-DBMCs 
As shown in Figs. 1 and 2, due to increased 
percentages of CD11cint and B220+ in IL-15-DBMCs, 
we presumed that these two markers are associated 
with the IFN-γ-producing capacity of IL-15-DBMCs. 
Although we showed no expression alterations of NK 
cell-specific CD49b and NK1.1 or T cell-specific CD4 
and CD8 molecules in IFN-γ-producing CD11cint 
IL-15-DBMCs and BMDCs (Fig. 2C and Fig. S3), we 
further investigated lymphoid cell lineage-specific 
markers to exclude the possible expansion of these 
cells due to their IFN-γ-producing abilities. In 
addition, cells with the CD11cintB220+ phenotype were 
heterogeneous, as these markers were expressed not 
only by diverse DC subsets but also by B, T, and NK 
cells (56). Therefore, we evaluated differences in the 
expression of B-, T-, or NK cell-associated surface 
markers between BMDCs and IL-15-DBMCs, and we 
found no relationships with these markers except for 
Thy1.2 and B220 (Fig. S4). The number of 
IL-15-induced CD11cintB220+ cells was approximately 
6 x 106 cells/mouse, but only 3 x 105 cells/mouse were 
generated in BMDCs after 6 days of culture, 
suggesting that IL-15 induced the expansion of this 
IFN-γ−producing cell population. Only the 
LPS-stimulated CD11cintB220+ subpopulation, not the 
rest of the generated population, in IL-15-DBMCs 
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displayed increased IFN-γ levels compared with those 
of the control cells and BMDCs by intracellular 
molecule staining analysis, which was consistent with 
the ELISA results (Fig. 3A, B). These results indicate 
that IFN-γ production followed by LPS stimulation in 
IL-15-DBMCs are related in CD11cintB220+ cells. 
Moreover, we further observed additional cell surface 
markers that have been associated with 
IFN-γ-secreting cell populations such as ILCs (Fig. 
3C). Because the rate of B220+ cells from both groups 
of cells was very low, we enriched the B220+ 
population by MACS and analyzed the level of 
phenotype markers. Although expression of CD127 
was not significantly different among the different 
populations, the percentages of cells expressing Sca-1 
and Thy1.2 were markedly increased in the 
B220-enriched CD11cint population derived from 
IL-15-DBMCs (Fig. 3C). 
Thy1.2 is a specific marker for 
IFN-γ-producing CD11cintB220+ IL-15-DBMCs 
Thy1.2 and Sca-1 have been reported as surface 
markers of ILCs, including ILC1s associated with 
IFN-γ production (57-59). To confirm whether Thy1.2 
is a characteristic marker of IFN-γ-producing 
IL-15-DBMCs based on the present results (Fig. 3C), 
we examined the effect of Thy1.2. First, we sorted 
Thy1.2+ cells from both BMDCs and IL-15-DBMCs by 
flow cytometry using an anti-mouse Thy1.2 antibody. 
There was no difference among the populations of 
Thy1.2+ cells in each group (Fig. 4A). Next, Thy1.2+ 
cells of each group were enriched using B220+ 
MicroBeads and MACS separators. The 
LPS-stimulated Thy1.2+ and B220-enriched cells (Fig. 
4B, left panel) from IL-15-DBMCs exhibited a higher 
level of the CD11cint population than the other cell 
groups. This cell population comprised 85% of the 
Thy1.2+CD11cintB220+ population, which expressed 
 
 
Figure 3. CD11cintB220+ population in IL-15-DBMCs is a major producer of IFN-γ and immunophenotypically differs from BMDCs by differentially 
expressing Sca-1 and Thy1.2. (A) BMDCs and IL-15-DBMCs stimulated with LPS for 6 h with GolgiStop were analyzed for the expression of IFN-γ by an intracellular 
staining (ICS) assay. The numbers in the plots represent the percentage of the corresponding population. (B) The bar graph represents the mean ± SD (n = 3) of the IFN-γ+ 
population in gated areas of CD11cintB220+ and other cells. (C) BMDCs and IL-15-DBMCs were enriched for the B220+ population by MACS, and CD11cintB220+ cells from 
each population were stained for the indicated markers. The results are presented as the mean ± SD (n = 3). The significance of the difference was determined using an 
unpaired t-test. n.s.; not significant, ***p < 0.001 comparison between CD11cintB220+ cells from BMDCs and IL-15-DBMCs. 
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significantly higher levels of IFN-γ than other groups 
(Fig. 4B). As displayed in Fig. 4B, these results suggest 
that the CD11cintB220+-expressing Thy1.2 population 
in IL-15-DBMCs is associated with IFN-γ production. 
Confirmation of phenotypic markers on 
IFN-γ-producing IL-15-DBMCs 
Next, we attempted to confirm whether the 
discovered markers may be distinct markers for 
IFN-γ-producing IL-15-DBMCs by inverse FACS 
gating of intracellularly IFN-γ-expressing 
IL-15-DBMCs. Before that, we confirmed that these 
IFN-γ producing capacities of IL-15-DBMCs were 
consistent with the ELISA results (Fig. S5). Upon 
depletion using B220 and Thy1.2 Microbeads, the 
capacity of LPS-treated B220 or Thy1.2-depleted 
IL-15-DBMCs to produce IFN-γ was significantly 
reduced. On the other hand, when CD19 was deficient 
in IL-15-DBMCs, marginally decreased IFN-γ 
production was observed. This reduction might be 
partly due to the loss of CD19+ cells co-expressing 
B220, and it indicated that B cells were not related to 
IFN-γ-producing cells (Fig. S5A, B and C). Notably, 
the intracellular appearance of IFN-γ was shown in 
the B220+, Thy1.2+, CD11cint, and Sca-1+ populations 
from LPS-treated B220-enriched IL-15-DBMCs (Fig. 
S6). Thus, we investigated whether the increased 
levels of LPS-stimulated IFN-γ in IL-15-DBMCs was 
induced by Sca-1+ cells in the Thy1.2+CD11cintB220+ 
subpopulation. First, we measured the intracellular 
levels of IFN-γ by flow cytometry using the Golgi 
blocker brefeldin A (BFA). The accumulation of 
intracellular IFN-γ in B220-enriched IL-15-DBMCs 
was nine-times more robust than that of the other 
groups (Fig. 5A). Next, we investigated whether the 
targeted cell surface markers could play a role in 
 
 
Figure 4. Thy1.2 is a key phenotypic marker for IFN-γ-producing B220+ IL-15-DBMCs. One representative plot from three independent experiments is described. 
(A) Thy1.2+ cells were isolated from BMDCs and IL-15-DBMCs. The numbers in the plots represent the percentage of the corresponding population. (B) Thy1.2- cells and the 
B220-enriched/depleted population from Thy1.2+ cells were analyzed for the expression of IFN-γ by ICS assay. The numbers in the plots represent the percentage of the 
corresponding population.  
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IFN-γ production. Importantly, the significant 
increase in the level of IFN-γ production in the B220+, 
Thy1.2+, CD11cint, and Sca-1+ populations occurred 
only after B220-enriched IL-15-DBMCs were treated 
with LPS (Fig. 5B). Collectively, these data suggest 
that the source of IFN-γ is the 
CD11cintB220+Thy1.2+Sca-1+ population from 
IL-15-DBMCs. As displayed in Fig. 5C, IL-15-DBMCs 
were analyzed and then confirmed by backgating 
from IFN-γ+ cells using a flow cytometry strategy. 
Approximately 3.3 x 106 cells/mouse of 
IFN-γ-associated CD11cintB220+Thy1.2+Sca-1+ cells 
were generated. These results indicate that IL-15 
treatment generates cells that are functionally and 
phenotypically similar to both Sca-1+Thy1.2+ 
ILC1-like cells and B220+CD11cint IKDCs-like cells as 
the major subset of IFN-γ producing cells, apart from 
NK cells, indicating that IFN-γ-producing 
IL-15-DBMCs resemble both cell types by reciprocally 
expressing specific markers of both cell types. 
IL-15 expands IFN-γ-producing IL-15-DBMCs 
in freshly isolated mouse bone marrow 
To further check whether IL-15 directs the 
expansion of pre-existing IL-15-DBMCs or induces the 
differentiation of IL-15-DBMCs, bone marrow was 
freshly isolated from mice. Interestingly, 1.5 x 104 cells 
expressing CD11cintThy1.2+Sca-1+B220+ were 
observed, which constituted 0.03% of the total bone 
marrow cells (Fig. 6A). Moreover, this IL-15-DBMC 
population was not associated with the NK1.1 surface 
marker (Fig. 6B), suggesting that the NK cell-derived 
IFN-γ-producing capacity upon LPS stimulation may 
be excluded as we consistently described. Based on 
this pre-existence, we examined the expansion of 
IL-15-DBMCs in a time-dependent manner. When 
treated with IL-15 under the DC-generating condition, 
the CD11cint-expressing population consistently 
started to expand, and the proportion of 
Thy1.2+Sca-1+B220+ cells among the CD11cint cells was 
 
 
Figure 5. CD11cintB220+Thy1.2+Sca-1+ cells are a major source of IFN-γ production in IL-15-DBMCs. B220+-enriched/depleted BMDCs and IL-15-DBMCs were 
stimulated with LPS for 6 h with GolgiStop and were analyzed for the expression of IFN-γ by ICS assay. (A) The numbers in the plots represent the proportion of the IFN-γ+ 
subset to total cells. (B) The portion of IFN-γ+ and positive indicated markers in B220-enriched and B220-depleted BMDCs and IL-15-DBMCs (mean ± SD; n = 3). The significance 
of the difference was determined using an unpaired t-test. ***p < 0.001 compared to B220-enriched or B220-depleted BMDCs. (C) IL-15-DBMCs were further confirmed by 
backgating target markers from IFN-γ+ cells. BMDCs were backgated using target markers. One representative plot from three independent experiments is described. The 
numbers in the plots represent the percentage of the corresponding population. 
Int. J. Biol. Sci. 2019, Vol. 15 
 
 
http://www.ijbs.com 
474 
significantly increased from the beginning of culture. 
This increased cell population was not observed 
under the GM-CSF-only condition (Fig. 6C and D). 
These results demonstrated that IL-15 induced the 
expansion of the pre-existing CD11cintThy1.2+Sca-1+ 
B220+ cell population rather than generating a new 
cell population. 
IFN-γ-producing Thy1.2+B220+ IL-15-DBMCs 
contribute to the control intracellular Mtb 
infection 
IFN-γ is widely believed to have an essential role 
in controlling tuberculosis (60-63). This cytokine is 
mainly produced by Th1 cells, which have a key role 
in Mtb resistance. IFN-γ activates infected 
macrophages, which kill bacteria through the 
production of nitric oxide, reactive nitrogen 
intermediates, and reactive oxygen species (64). In 
addition, CD8+ T cells, innate lymphocytes, NK cells 
and NKT cells can produce IFN-γ. However, while 
Mtb migrates from the lung to other organs during the 
initial resident phase within seven to nine days, 
permissive macrophages accumulate in the lung, 
resulting in the delayed arrival of Mtb-specific T cells 
at the primary infection site, which occurs within 
18-20 days (65). 
According to these findings, a robust early 
innate immune response to Mtb infection was 
expected to help limit bacterial growth. In this study, 
Mtb H37Rv-infected BMDMs were co-cultured with 
IL-15-DBMCs, which were enriched for the presence 
or absence of Thy1.2 and B220 using flow cytometric 
analysis (Fig. 7A). Given that Mtb has been reported 
to activate TLR2 (66) and that IL-15-DBMCs can 
produce IFN-γ upon TLR2 activation using 
Pam3CSK4 (Fig. S1), the Thy1.2- and B220-enriched 
cell population produced significant levels of IFN-γ in 
response to Mtb infection (Fig. 7A). 
 
 
Figure 6. IL-15 directly contributes to the expansion of the CD11cintThy1.2+Sca-1+B220+ cell population from bone marrow. (A) Freshly isolated mouse bone 
marrow samples were surface stained with the indicated surface markers. The numbers in the plots represent the percentage of the corresponding population. (B) 
IL-15-DBMC-derived target cell populations were further stained with the NK1.1 surface marker. The numbers in the plots represent the percentage of the corresponding 
population. The results are presented as the mean ± SD (n = 5). (C) The expression of CD11c, Thy1.2, Sca-1 and B220 was compared between DCs and IL-15-DBMCs. The 
number of squares indicates the percentage of the corresponding population. (D) The absolute number of the corresponding population in each group of cells is represented by 
the bar graph (mean ± SD; n = 4). 
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Figure 7. IFN-γ-producing sorted B220+Thy1.2+ cells from IL-15-DBMCs restrict intracellular growth of Mycobacterium tuberculosis in BMDMs. (A) Thy1.2- 
and B220-enriched or Thy1.2- and B220-depleted cell populations derived from IL-15-DBMCs were harvested through FACSAria sorting. Then, IL-15-DBMC-derived 
populations enriched or depleted in B220 and Thy1.2 were stimulated with Mtb, and the levels of IFN-γ in the cell supernatant were analyzed. (B) IL-15-DBMC-derived B220- 
and Thy1.2-enriched/depleted cells were added to Mtb-infected macrophages, and the intracellular proliferation of bacteria was monitored after three days of co-culture. CFU 
are representative of two independent experiments. (C) Conditioned media derived from B220- and Thy1.2-enriched/depleted cells were added to Mtb-infected wild-type and 
IFN-γR-/- macrophages, respectively. Then, the intracellular proliferation of bacteria was monitored after three days of co-culture. CFU are representative of two independent 
experiments. DP, double positive; DN, double negative. (D) The levels of NO were detected by Griess reagent. The results are presented as the mean ± SD (n = 3). One-way 
ANOVA followed by Tukey’s multiple comparison test was used to evaluate statistical significance. n.s.; not significant, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Based on IFN-γ-producing capacity, cells were 
lysed and spotted onto 7H10 plates on day three of 
co-culture. After 3 weeks of incubation, the CFU were 
counted. As a positive control, 50 ng/ml of IFN-γ, 
known for its killing effect on Mtb (67,68), was added 
to infected macrophages, and bacterial growth was 
observed (Fig. 7B). To further confirm the 
IFN-γ-derived protective effect, IFN-γR-/- BMDMs 
were infected with Mtb and co-cultured with 
double-positive- and double-negative-conditioned 
media with or without Pam3CSK4 stimulation, 
respectively (Fig. 7C). Compared to the groups of 
macrophages mixed with Thy1.2- and B220-depleted 
cells or culture media only, the group incubated with 
IL-15-DBMC-derived Thy1.2- and B220-enriched cells 
showed suppressed bacterial growth (Fig. 7B). In 
addition, conditioned media from Thy1.2- and 
B220-enriched cells only displayed a protective effect 
against Mtb infection compared with wild-type 
BMDMs cultured with double-negative-conditioned 
media. Importantly, conditioned media-co-cultured 
IFN-γR-/- BMDMs did not show any 
bacterial-suppressive effects, suggesting that 
double-positive cell population-derived soluble IFN-γ 
production may play an important role in BMDM 
bacterial killing effects (Fig. 7C). Collectively, the 
results indicated that this protection was 
accompanied by enhanced nitric oxide secretion 
resulting from Thy1.2+B220+ cell-dependent IFN-γ 
production (Fig. 7B, C, and D). These results indicate 
that the killing effect of BMDMs against Mtb infection 
is mediated by IFN-γ production by Thy1.2+B220+ 
IL-15-DBMCs. 
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Discussion 
IL-15 alone and IL-15-primed cells have gained 
increasing interest because of their therapeutic 
potential against cancers and infectious diseases. 
IL-15 is known not only for being involved in 
developing progenitor cells into DCs (21,22) but also 
for inducing the proliferation and maintenance of T 
cells, ILCs and NK cells (69). In addition, when 
generating DCs from bone marrow via IL-15 
treatment, IL-15-primed DCs have exhibited the 
ability of producing IFN-γ (13,25). Administration of 
IFN-γ is commonly known for reducing the number 
of bacteria (67,68). In addition, IFN-γ-producing cells 
of the myeloid cell lineage were shown to improve the 
survival rate of infected mice (70). Although IL-15 has 
been reported to stimulate IFN-γ production in 
myeloid cells, the use of IL-15 in the phenotypic 
definition of IL-15-DBMCs is still controversial 
because the phenotypic markers of these cells are 
occasionally confused with that of pre-mNK cells, 
NKDCs, IKDCs, and ILC1s.  
Therefore, we first investigated and compared 
the phenotype of IL-15-DBMCs with that of BMDCs. 
IL-15-DBMCs displayed a higher level of IFN-γ after 
LPS treatment (Fig. 1A). Moreover, the population of 
CD11chiMHC-II+-matured DCs was reduced, and 
IL-15-DBMCs instead consisted of more CD11cint cells, 
which is considered one of the characteristics of 
IFN-γ-producing cells (Fig. 1D and Fig. 2A, B). These 
data support the concept that IL-15-DBMCs has a 
distinct phenotype and the association between the 
CD11cint population and IFN-γ production.  
In previous studies, several types of innate cells 
were reported to have the capacity to produce IFN-γ, 
such as IKDCs and ILC1s that include NK cells and 
immature myeloid cells with ring-shaped nuclei (29). 
Although NK and T cells were originally reported as 
major sources of IFN-γ production in response to 
microbial infections, an earlier production of IFN-γ by 
immature myeloid cells than that by NK and T cells 
and IFN-γ-producing neutrophils have recently been 
described (27,70), suggesting both the redundancy in 
the T cell- and NK cell-mediating IFN-γ-dependent 
protection and the contribution of myeloid-derived 
IFN-γ-producing innate immune cells in response to 
infection. Still, the issue of myeloid-derived IFN-γ 
production has been controversial partly because of 
obscurities in distinguishing the exact source of 
myeloid cells from NK and T cells (27).  
Additionally, when 1 µg/ml of Poly(I:C), known 
as a stimulator of NK cells, was added to stimulate 
cells, IFN-γ was not detected in either of the two types 
of cells (Fig. S1B) (71). Moreover, B-, T-, and NK 
cell-associated surface markers were not related to 
either BMDCs or IL-15-DBMCs (Fig. S4). IKDCs have 
been reported to be CD11cintB220+DX5+ (or NK1.1+) 
and Gr-1- (29,31,34). pDCs, a type of DC, are also 
known to express intermediate levels of CD11c, and 
Siglec-H and PDCA-1 have been shown to be specific 
markers for pDCs (33,72,73). IL-15-DBMCs showed 
refractory expression of specific markers for pDCs 
(Fig. 2C). Specifically, the B220+ population was 
significantly increased in the IL-15-DBMCs (Fig. 2C), 
suggesting that IL-15-DBMCs might constitute a 
different subset of cDCs, pDCs, and NK cells but may 
be functionally more similar to IKDCs, although these 
two types of cells do not exhibit the identical 
phenotype of CD11cintB220+ surface markers, except 
for DX5 and NK1.1. Based on the present study, we 
hypothesized that CD11cintB220+ cells have the 
capacity of producing IFN-γ. As expected, this 
population in IL-15-DBMCs showed increased IFN-γ 
levels (Fig. 3A and B). Although there was a 
significant difference in level of IFN-γ between the 
B220-depleted population and IL-15-DBMCs, we 
detected a low level of IFN-γ in the B220-depleted 
population, which was inconsistent with our 
prediction. This result could be explained by the 
purity of the cell population, as we used an LS column 
for cell enrichment (Fig. 5A and Fig. S5A). A previous 
study showed that CpG treatment in mice stimulated 
the expression of IFN-γ-producing Thy1.2+ DCs in the 
spleen (74). Based on our present findings and the 
reported results, other intriguing phenotypic markers 
were investigated. Interestingly, we found that Sca-1 
and Thy1.2 were significantly increased in 
IL-15-DBMC-derived CD11cintB220+-enriched cells 
(Fig. 3C). Our studies are the first to reveal that 
IL-15-derived CD11cintB220+ cells displayed increased 
levels of both Thy1.2 and Sca-1 expression. 
Given that Thy1.2 and Sca-1 have been reported 
as ILC markers (41,75), we next examined the 
association of IFN-γ production and Thy1.2 and Sca-1 
expression in these cells (Fig. 4 and Fig. S5C). Our 
results clearly point to an increase in the population of 
IFN-γ-producing cells gated on target markers. 
Therefore, IL-15 treatment induces functionally 
similar ILC1 populations that produce IFN-γ and 
require IL-15 to express Thy1.2 and Sca-1 markers, 
thus displaying differential expression of CD11c and 
B220 between ILC1- and IL-15-DBMC-derived IFN-γ 
producing cells (Fig. 5C). Overall, IL-15 treatment 
during dendritic cell differentiation generates 
IFN-γ-producing cells by directing the expansion of 
cell population (Fig. 6), and these IFN-γ-producing 
capacities are characterized by the co-expression of 
CD11cintB220+ and Thy1.2+Sca-1+ by both IKDC- and 
ILC1-associated markers. Surprisingly, the 
pre-existing CD11cintB220+Thy1.2+Sca-1+ cell 
population in freshly isolated bone marrow did not 
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produce IFN-γ upon LPS stimulation (data not 
shown), suggesting that IL-15 may induce the 
expansion of this cell population as well as reprogram 
the cells that possess IFN-γ-producing abilities. In 
addition, the number of this cell population might be 
not enough for observing IFN-γ production, which 
only constituted 0.03% of the total bone marrow cells. 
This observation will be further investigated in our 
future study. Taken together, the data indicate that 
IL-15 directly contributes to the expansion of 
IFN-γ-producing IL-15-DBMCs that differ 
phenotypically from B, NK, and T cells by expressing 
both B220 and Thy1.2 markers.  
IFN-γ is a principal cytokine involved in both the 
innate and adaptive immune responses (76), and the 
capacity to produce IFN-γ is considered a protective 
effect against infections (70,74). In particular, the 
important role of IL-15 has been reported in the 
generation of protective immunity and vaccine 
development as an adjuvant. For example, IL-15 has 
been shown to protect against Mtb infection in IL-15 
transgenic and KO mice studies and through 
exogenous IL-15 injection (77,78) by potentiating T 
cell proliferation. In addition, IL-15 demonstrated its 
adjuvant effect in boosting an antigen-specific 
immune response. For example, IL-15 enhanced the 
anti-Mtb vaccine efficacy of recombinant BCG by 
generating durable antigen-specific memory CD4+ 
and CD8+ T cells and inducing the production of 
IFN-γ in response to antigen 85B (79). This 
IL-15-related IFN-γ production was found to 
potentiate the phagocytic function and antimicrobial 
activity of macrophages and to orchestrate the 
adaptive immune response through up-regulated 
antigen presentation in dendritic cells, resulting in 
enforced T cell immune responses (80,81). 
In the present study, co-culturing Mtb-infected 
murine BMDMs with sorted IFN-γ-producing 
IL-15-DBMCs prevented bacterial growth. This result 
is in line with previous studies showing the 
immunoprotective activity of IFN-γ-producing 
cells (74). Interestingly, suppressive activity of 
BMDMs co-cultured with IFN-γ-producing 
IL-15-DBMCs in bacterial growth is superior to that of 
BMDMs treated with recombinant IFN-γ alone, 
indicating that another factor may be involved in this 
killing activity other than the increased NO 
production. However, as one possible explanation or 
mechanism, we clearly demonstrated that protection 
against Mtb infection was controlled by IFN-γ 
production by Thy1.2+B220+-IL-15-DBMCs (Fig. 7B, C 
and D). Thus, further investigations into the 
mechanism involved in the killing effect of 
IFN-γ-producing IL-15-DBMCs on Mtb infection are 
required to clarify whether this cell type can be used 
in the treatment of TB-infected patients. Taken 
together, the prompt initiation of IFN-γ-activated 
mechanisms in infected macrophages could be 
beneficial in eliminating Mtb infection before the 
bacteria actively propagate inside the host.  
Obviously, our present study has several 
limitations that require further investigation. First, the 
exact origin of this IFN-γ-producing IL-15-DBMC 
population should be determined to define the 
associated cell lineage. Recently, Belyaev et al. 
identified the emergence of an atypical progenitor 
subset with both lymphoid and myeloid potential in 
Plasmodium chabaudi-infected mice (82). Thus, 
understanding how the progenitor compartments 
respond to environmental and pathophysiological 
conditions will define key mechanisms for the 
selective regulation of differentiation and 
proliferation of IFN-γ-producing IL-15-DBMCs. 
Second, IFN-γ-producing IL-15-DBMCs can play a 
key role in the immediate protection against Mtb 
infection in vivo prior to the initiation of the Th1 
immune response. We are currently investigating 
whether this cell type exists in vivo after IL-15 injection 
with various TLR agonists. Obviously, whether 
phenotypically similar IL-15-DBMCs exist in humans 
for the purpose of future clinical applications should 
be determined. Moreover, this investigation could be 
strengthened by using single-cell RNA-sequencing to 
identify novel cell subsets (83). Additionally, we are 
currently investigating the applications of 
IFN-γ-producing IL-15-DBMCs in Mtb treatment and 
vaccine development by enforcing the innate immune 
responses via the transfer of IFN-γ-producing 
IL-15-DBMCs into mice susceptible to Mtb infection, 
which are highly susceptible due to delayed IFN-γ 
responses. These limitations have also been associated 
with endless controversies in terms of identifying cell 
subsets, especially between IKDCs and NK cells, 
because of phenotypical obscurities. Based on 
developmental and functional overlaps, IKDCs have 
been regarded as one of the subsets of NK 
cells (56,84,85). Although IFN-γ-producing 
IL-15-DBMCs also displayed overlapping surface 
markers, these generated cells are different given that 
CD11cintB220+ cells do not express NK1.1 and CD49b 
cells display the exact same pattern as generated 
BMDCs (Fig. 2C and Fig. S3). In addition, 
IFN-γ-producing IL-15-DBMCs did not respond to the 
NK cell agonist, Poly(I:C) (Fig. S1B). However, the cell 
lineages or progenitors that are regulated upon IL-15 
treatment should be addressed in our next study since 
hematopoiesis occurs in bone marrow (86). Although, 
the pre-existence of CD11cintThy1.2+Sca-1+B220+ cells 
were identified in freshly isolated bone marrow, it 
will be further investigated whether IL-15 directed 
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expansion of this cell population or even influenced 
differentiation of bone marrow cell progenitors apart 
from pre-existing cell population. This study will 
facilitate the identification of cell subsets more clearly, 
even in in vivo experiments with IL-15-injected mice to 
overcome our limitations. Nevertheless, to the best of 
our knowledge, our study revealed for the first time 
that IL-15 drives the expansion of IFN-γ-producing 
CD11cintB220+Thy1.2+Sca-1+ from bone marrow in a 
GM-CSF-dependent manner; moreover, this cell 
subset co-expresses lymphoid-myeloid lineage 
phenotypic markers and shows therapeutic potential 
against Mtb infection in the in vitro macrophage 
system.  
In conclusion, IFN-γ-producing IL-15-DBMCs 
can be redefined as CD11cintB220+Thy1.2+Sca-1+ cells, 
which phenotypically resemble both IKDCs or 
pre-mNK and ILC1s, and could be a therapeutic 
potential to control intracellular Mtb growth inside 
macrophages by potentiating the IFN-γ-NO axis. The 
current challenges are to further investigate the 
development of IFN-γ-producing IL-15-DBMCs into 
ILC1s and IKDCs or pre-mNK cells and to identify the 
origin, the existence, and the human counterpart of 
this cell type.  
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